Syneos Health (NASDAQ: SYNH) scored a 0.04 media view on the Accern Sentiment’ds scale. Syneos Health startup works as a combined biopharmaceutical solutions company. Critical Analysis; Syneos Health (SYNH) and Anavex Life Sciences (AVXL)$770.78 Million in Sales Expected for Syneos Health Inc (SYNH) This QuarterSyneos Health (SYNH) Stock Rating reaffirmed by Goldman SachsSyneos Health (SYNH) Downgraded to C at TheStreetZacks; Brokerages Anticipate Syneos Health Inc (SYNH) to Announce $0.53 EPSValuEngine reduced Syneo Health shares from a hold to a sell in an analysis released on 2nd April 2018. Eight of the analysts gave a buy valuation on the Syneos Health. Syneos Health will record 2.28 earnings per share for the present financial year.

Source: The North Africa Journal April 17, 2018 05:03 UTC